A systematic review of studies focused on strategies to improve patient comfort and compliance with radiotherapy treatment plans, finding that aromatherapy strategies show promise in this setting.
The FDA’s accelerated approval of the PARP inhibitor rucaparib brings clinical prostate oncology into the precision medicine era.
Dr Sue Yom discusses the evolution and future of stereotactic body radiotherapy.
The consensus guideline, drafted by an ASTRO-convened expert task force, offers recommendations about radiotherapy, including brachytherapy, and chemoradiation, in different stage-of-disease and treatment-strategy settings.
A decade since the first wave of mobile device health apps hit the market there remain few designed specifically for patients who are undergoing radiation therapy for cancer. This review offers some useful tools available for patient education, organization, and coping.
Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL.
A nationwide outbreak of EVALI reports has highlighted the unknowns about one of the most popular forms of inhalation drug use in the US.
Results from the phase 3 S-TRAC clinical trial suggested that for selected young and otherwise healthy patients, toxicities of sunitinib are manageable.
The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).
Inotuzumab ozogamicin (InO) exhibits clinical efficacy against heavily pretreated, relapsed CD22-positive pediatric B-cell acute lymphoblastic leukemia (B-ALL).
